ArticleBMC veterinary research2026
Use of plasma chromogranin a epitopes vasostatin and catestatin as biomarkers for catecholamine-producing tumours in dogs.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferentiation of catecholamine-producing tumours from other adrenal tumours remains difficult. Chromogranin A (CgA) is a marker for catecholamine secretion in the body. An assay for quantification of the CgA epitopes vasostatin and catestatin has been validated for use in dogs but not yet evaluated in dogs with catecholamine-producing tumours. The aims were to evaluate the assays foranalysis of plasma concentrations of the CgA epitopes vasostatin and catestatin in dogs with adrenal tumours and to compare concentrations between catecholamine-producing tumours and adrenocortical tumours in dogs that were subjected to adrenalectomy. Twelve dogs with histopathologically confirmed catecholamine-secreting tumours (eleven pheochromocytomas (PCCs), one extra-adrenal sympathetic paraganglioma (PGL)) and twelve with adrenocortical tumours were included in the study. Plasma concentrations of the CgA epitopes vasostatin and catestatin were determined byradioimmunoassay (RIA), before adrenalectomy in 23 out of 24 dogs and after adrenalectomy in six of the dogs with catecholamine-secreting tumours (five PCC, one PGL). Tumour diagnosis was made by histopathology in all cases.
resultsOverall, median plasma concentration of the CgA epitopevasostatin in dogs with catecholamine-secreting tumours was 0.82 nmol/L (interquartile range (IQR) 0.52 to 1.60 nmol/L), which was significantly higher(Wilcoxon rank sum exact test, P= 0.0374) than the vasostatin concentration in adrenocortical tumours (median 0.50; IQR 0.34 to 0.59 nmol/L). A subsetof dogs (5/12) with catecholamine-secreting tumours had elevated plasma vasostatin concentrations preoperatively. After successful surgery, thepreoperatively elevated plasma vasostatin concentrations decreased numerically, however without reaching statistical significance. Catestatin concentrationdid not differ between tumour types.
conclusionsElevated plasma concentration of the CgA epitope vasostatin showed potential as a biomarker for asubset of catecholamine-secreting tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.